Keywords
POD24
No Hodgkin lymphomas
FLIPI
How to Cite
Abstract
Follicular lymphoma is an indolent lymphoma with potential relapses in the course of its evolution. In the last few years, new therapeutic strategies have improved patient´s survival. However, a high risk subgroup progresses early with a shorter overall
survival. Our primary objective is to report the incidence of POD24 and its impact on OS and, as a secondary objective, to evaluate the association of the FLIPI 1, FLIPI 2 and PRIMA PI scores and the clinical-metabolic variables with the risk of a POD24
event. Three hundred and thirty-two patients were included, 46 patients (13.8%) with a POD24 event.
Factors independently associated with greater probability of a POD24 event were: presence of B symptoms (OR 2.09) and elevated LDH (OR 1.27). In
this study we report a significant difference in OS between POD24 vs NO POD24 (at 60 months, 63 vs 95% with p <0.001) reinforcing the POD24 impact as a negative prognostic factor. Despite being a retrospective study and the limited number of patients, we report local data not available to date. New clinical and/or biological markers will be necessary to identify the subgroup with POD24 risk, which could benefit from an adapted therapy.
References
Solal-Céligny P, Roy P, Colombat P y col. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
Federico M, Bellei M, Marcheselli L y col. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555-4562.
Bachy E, Maurer MJ, n TMHaberman y col. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49-58.
Casulo C, Byrtek M, Dawson KL y col. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J ClinOncol. 2015;33(23):2516-2522.
Casulo C y col. Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials. Blood. 2017;130:412.
Sorigue M y col. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. HematolOncol. 2017;35(4):520-527.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar